{"id":"ranibizumab-and-laser","safety":{"commonSideEffects":[{"rate":null,"effect":"Endophthalmitis"},{"rate":null,"effect":"Retinal detachment"},{"rate":null,"effect":"Cataract progression"},{"rate":null,"effect":"Intraocular pressure elevation"},{"rate":null,"effect":"Floaters"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ranibizumab is a monoclonal antibody fragment that inhibits VEGF-A, a key driver of pathological neovascularization and vascular permeability in retinal diseases. The combination with laser therapy provides dual mechanisms: anti-VEGF suppression of abnormal vessel formation and growth, plus direct thermal ablation of ischemic or neovascular retinal areas. This combination approach targets both the molecular driver and the structural pathology of proliferative retinal disease.","oneSentence":"Ranibizumab blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth and leakage in the retina, while laser photocoagulation thermally destroys abnormal retinal tissue.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:03:56.859Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Proliferative diabetic retinopathy"},{"name":"Retinal vein occlusion with neovascularization"}]},"trialDetails":[{"nctId":"NCT06985706","phase":"PHASE3","title":"Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns","status":"RECRUITING","sponsor":"Belfast Health and Social Care Trust","startDate":"2025-05-19","conditions":"Severe Diabetic Macular Oedema","enrollment":264},{"nctId":"NCT04444492","phase":"PHASE3","title":"Combination of Ranibizumab and Targeted Laser Photocoagulation","status":"RECRUITING","sponsor":"University of Giessen","startDate":"2020-08-25","conditions":"Central Retinal Vein Occlusion With Macular Edema","enrollment":110},{"nctId":"NCT04075136","phase":"PHASE4","title":"Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2023-03-30","conditions":"Exudative Age Related Macular Degeneration","enrollment":""},{"nctId":"NCT00606138","phase":"PHASE1, PHASE2","title":"Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2008-01","conditions":"Proliferative Diabetic Retinopathy","enrollment":9},{"nctId":"NCT02640664","phase":"PHASE3","title":"Rainbow Extension Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-06-16","conditions":"Retinopathy of Prematurity (ROP)","enrollment":180},{"nctId":"NCT05716932","phase":"","title":"Focal Laser Single Intravitreal Ranibizumab Retinal Artery Macroaneurysm.","status":"COMPLETED","sponsor":"Dar El Oyoun Hospital","startDate":"2022-12-22","conditions":"Retinal Artery Macroaneurysm","enrollment":14},{"nctId":"NCT05701124","phase":"PHASE3","title":"Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2020-11-20","conditions":"Retina Disease, Retinopathy of Prematurity, Ranibizumab","enrollment":30},{"nctId":"NCT03690947","phase":"PHASE4","title":"Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME","status":"COMPLETED","sponsor":"Beijing Hospital","startDate":"2018-10-01","conditions":"Diabetic Macular Edema","enrollment":72},{"nctId":"NCT03054766","phase":"NA","title":"Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO","status":"COMPLETED","sponsor":"Beijing Hospital","startDate":"2017-02-14","conditions":"Branch Retinal Vein Occlusion, Ranibizumab, Laser Photocoagulation","enrollment":80},{"nctId":"NCT01469156","phase":"PHASE1, PHASE2","title":"Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy","status":"COMPLETED","sponsor":"Southeast Retina Center, Georgia","startDate":"2011-09","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":20},{"nctId":"NCT00667472","phase":"PHASE1","title":"Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks","status":"WITHDRAWN","sponsor":"University of California, Irvine","startDate":"2008-03","conditions":"Port-Wine Stain","enrollment":""},{"nctId":"NCT04985448","phase":"","title":"Real World Study of the Effectiveness and Safety of Conbercept Ophthalmic Injection in the Treatment of Retinopathy of Prematurity - Multicenter, Retrospective and Observational Study Based on Real World Data","status":"UNKNOWN","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2022-09","conditions":"Retinopathy of Prematurity","enrollment":1000},{"nctId":"NCT05186155","phase":"","title":"Analysis of Ocular and Neurodevelopmental Function for Retinopathy of Prematurity","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-01-01","conditions":"Retinopathy of Prematurity, Neurodevelopmental Abnormality","enrollment":510},{"nctId":"NCT01934556","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Palmetto Retina Center, LLC","startDate":"2013-11","conditions":"Diabetic Macular Edema","enrollment":150},{"nctId":"NCT01223612","phase":"PHASE4","title":"Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation","status":"COMPLETED","sponsor":"Moorfields Eye Hospital NHS Foundation Trust","startDate":"2010-10","conditions":"Diabetic Retinopathy","enrollment":37},{"nctId":"NCT04464694","phase":"PHASE4","title":"Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2020-09-01","conditions":"Proliferative Diabetic Retinopathy, Diabetic Macular Edema","enrollment":142},{"nctId":"NCT04332133","phase":"NA","title":"Outcomes of Subthreshold Laser Versus Intravitreal Injection of Ranibizumab in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Minia University","startDate":"2016-12","conditions":"Diabetic Macular Edema","enrollment":80},{"nctId":"NCT02953938","phase":"PHASE4","title":"Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-12-15","conditions":"Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)","enrollment":59},{"nctId":"NCT04186702","phase":"NA","title":"New Concepts in Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2014-09-10","conditions":"Diabetes Mellitus, With Complications","enrollment":150},{"nctId":"NCT00444600","phase":"PHASE3","title":"Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2007-03","conditions":"Diabetic Retinopathy, Diabetic Macular Edema","enrollment":691},{"nctId":"NCT01795209","phase":"PHASE4","title":"Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision","status":"TERMINATED","sponsor":"Seoul National University Bundang Hospital","startDate":"2013-01","conditions":"Branch Retinal Vein Occlusion, Macular Edema","enrollment":19},{"nctId":"NCT04062370","phase":"PHASE4","title":"Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-10-01","conditions":"Retinal Vein Occlusion, Treatment, Photocoagulation Burn to Retina","enrollment":100},{"nctId":"NCT03999125","phase":"PHASE4","title":"Anti-VEGF Therapy Versus Dexamethasone Implant for DME","status":"UNKNOWN","sponsor":"Sudhalkar Eye Hospital","startDate":"2019-06-25","conditions":"Clinically Significant Macular Edema Due to Diabetes Mellitus","enrollment":150},{"nctId":"NCT01846273","phase":"PHASE4","title":"Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-08-07","conditions":"Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy","enrollment":321},{"nctId":"NCT03904056","phase":"NA","title":"ETDRS PRP With IVR Versus Retinal Photocoagulation Targeted to Ischemic Retina With IVR for the Treatment of PDR","status":"COMPLETED","sponsor":"São Paulo State University","startDate":"2014-01-01","conditions":"Diabetic Retinopathy","enrollment":23},{"nctId":"NCT01594281","phase":"PHASE2","title":"Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-11","conditions":"Proliferative Diabetic Retinopathy (PDR)","enrollment":107},{"nctId":"NCT03609996","phase":"","title":"Retrospective Review of Proliferative Diabetic Retinopathy Patients","status":"UNKNOWN","sponsor":"Elman Retina Group","startDate":"2018-06-01","conditions":"Proliferative Diabetic Retinopathy","enrollment":100},{"nctId":"NCT02259088","phase":"PHASE3","title":"A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-11-05","conditions":"Diabetic Macular Edema, Visual Impairment","enrollment":384},{"nctId":"NCT03759860","phase":"PHASE4","title":"Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular Edema","status":"UNKNOWN","sponsor":"CynosureLutronic","startDate":"2018-01-08","conditions":"Diabetic Macular Edema","enrollment":12},{"nctId":"NCT02375971","phase":"PHASE3","title":"RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-12-30","conditions":"Retinopathy of Prematurity","enrollment":224},{"nctId":"NCT02218177","phase":"","title":"Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2014-08","conditions":"Age Related Macular Degeneration","enrollment":30},{"nctId":"NCT01552408","phase":"PHASE1, PHASE2","title":"Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)","status":"COMPLETED","sponsor":"David M. Brown, M.D.","startDate":"2012-03","conditions":"Diabetic Macular Edema","enrollment":29},{"nctId":"NCT02131350","phase":"PHASE4","title":"Combination Treatment of Intravitreal Ranibizumab, Focal/Grid Laser and Panretinal Photocoagulation in Patients With Diabetic Macula Edema","status":"COMPLETED","sponsor":"Shinshu University","startDate":"2014-04","conditions":"Diabetic Macula Edema","enrollment":40},{"nctId":"NCT03590444","phase":"PHASE4","title":"Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser","status":"COMPLETED","sponsor":"Hospital Hietzing","startDate":"2017-04-02","conditions":"Diabetic Retinal Edema","enrollment":50},{"nctId":"NCT01941329","phase":"PHASE2, PHASE3","title":"Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.","status":"COMPLETED","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2014-04","conditions":"High Risk Proliferative Diabetic Retinopathy","enrollment":94},{"nctId":"NCT02857491","phase":"NA","title":"Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-07","conditions":"Proliferative Diabetic Retinopathy","enrollment":90},{"nctId":"NCT01710839","phase":"PHASE4","title":"Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Charles C Wykoff, PhD, MD","startDate":"2012-10","conditions":"Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions","enrollment":30},{"nctId":"NCT01565148","phase":"PHASE2","title":"A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2012-02","conditions":"Diabetic Macular Edema","enrollment":185},{"nctId":"NCT00407381","phase":"PHASE2","title":"The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2006-12","conditions":"Diabetic Macular Edema","enrollment":126},{"nctId":"NCT00901186","phase":"PHASE2","title":"Efficacy and Safety of Ranibizumab (Intravitreal Injections) Versus Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-11","conditions":"Diabetic Macular Edema, Visual Impairment","enrollment":83},{"nctId":"NCT02059772","phase":"PHASE4","title":"Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema","status":"UNKNOWN","sponsor":"GWT-TUD GmbH","startDate":"2014-04-30","conditions":"Diabetic Macular Edema","enrollment":25},{"nctId":"NCT01599650","phase":"PHASE3","title":"Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Branch Retinal Vein Occlusion","enrollment":455},{"nctId":"NCT00445003","phase":"PHASE3","title":"Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2007-03","conditions":"Proliferative Diabetic Retinopathy, Diabetic Macular Edema","enrollment":333},{"nctId":"NCT02462304","phase":"PHASE4","title":"To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2015-06","conditions":"Diabetic Macula Edema","enrollment":60},{"nctId":"NCT01823965","phase":"PHASE2","title":"Intravitreal Injections of Ranibizumab With Deferred Laser Grid Laser Photocoagulation for Treatment of Diabetic Macular Edema With Visual Impairment","status":"COMPLETED","sponsor":"Poitiers University Hospital","startDate":"2011-10","conditions":"Diabetic Macular Edema","enrollment":35},{"nctId":"NCT01003106","phase":"PHASE1, PHASE2","title":"Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions","status":"COMPLETED","sponsor":"Peter A Campochiaro, MD","startDate":"2009-11","conditions":"Retinal Vein Occlusion","enrollment":81},{"nctId":"NCT02527733","phase":"PHASE4","title":"Retinal Sensitivity in BRVO After Anti-VEGF Therapy","status":"UNKNOWN","sponsor":"Fukushima Medical University","startDate":"2015-06","conditions":"Branch Retinal Vein Occlusion","enrollment":50},{"nctId":"NCT02522897","phase":"PHASE4","title":"Evaluation of the \"Treat-and-extend\" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas","status":"UNKNOWN","sponsor":"PD. Dr. med. Armin Wolf","startDate":"2015-08","conditions":"Central Retinal Vein Occlusion With Macular Edema","enrollment":60},{"nctId":"NCT01319188","phase":"PHASE4","title":"Ranibizumab and the Risk of Arterial Thromboembolic Events","status":"TERMINATED","sponsor":"Ural State Medical University","startDate":"2010-06","conditions":"Age-related Macular Degeneration, Coronary Artery Disease, Cerebrovascular Disorders","enrollment":380},{"nctId":"NCT00815360","phase":"PHASE2","title":"Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion","status":"COMPLETED","sponsor":"Retina Associates of Florida, P.A.","startDate":"2008-02","conditions":"Diabetic Macular Edema","enrollment":22},{"nctId":"NCT00841373","phase":"PHASE1, PHASE2","title":"Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease","status":"COMPLETED","sponsor":"Southern New England Retina Associates","startDate":"2007-07","conditions":"Retinal Ischemia","enrollment":1},{"nctId":"NCT01135914","phase":"PHASE3","title":"Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-07","conditions":"Diabetic Macular Edema","enrollment":241},{"nctId":"NCT01247220","phase":"PHASE2","title":"REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study","status":"COMPLETED","sponsor":"Retina Associates of Florida, P.A.","startDate":"2010-11","conditions":"Macular Edema, Branch Retinal Vein Occlusion","enrollment":12},{"nctId":"NCT01171976","phase":"PHASE3","title":"Efficacy and Safety of Ranibizumab in Two \"Treat and Extend\" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-09","conditions":"Diabetic Macular Edema","enrollment":373},{"nctId":"NCT00387582","phase":"PHASE2","title":"Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema","status":"COMPLETED","sponsor":"Rocky Mountain Retina Consultants","startDate":"2006-07","conditions":"Diabetic Retinopathy, Diabetic Macular Edema","enrollment":49},{"nctId":"NCT01198327","phase":"PHASE3","title":"Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Peter A Campochiaro, MD","startDate":"2010-08","conditions":"Retinal Vein Occlusion","enrollment":66},{"nctId":"NCT01325181","phase":"PHASE1, PHASE2","title":"Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy","status":"COMPLETED","sponsor":"Jang Won Heo","startDate":"2009-07","conditions":"Chronic Central Serous Chorioretinopathy","enrollment":34},{"nctId":"NCT00687804","phase":"PHASE3","title":"A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-05","conditions":"Diabetic Macular Edema","enrollment":345},{"nctId":"NCT01196325","phase":"","title":"Anterior and Posterior Segment Vascular Changes Following Laser and Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Diabetic Retinopathy","status":"UNKNOWN","sponsor":"University of Toronto","startDate":"2009-07","conditions":"Diabetic Macular Edema","enrollment":64},{"nctId":"NCT01746563","phase":"PHASE1, PHASE2","title":"Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2011-05","conditions":"Diabetic Retinopathy, Retinal Diseases, Eye Diseases","enrollment":30},{"nctId":"NCT00989989","phase":"PHASE3","title":"Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-09","conditions":"Diabetic Macular Edema","enrollment":396},{"nctId":"NCT01131585","phase":"PHASE3","title":"Safety and Efficacy of Ranibizumab in Diabetic Macular Edema","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-06","conditions":"Visual Impairment Due to Diabetic Macular Edema","enrollment":128},{"nctId":"NCT01255774","phase":"PHASE3","title":"Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy","status":"UNKNOWN","sponsor":"The New York Eye & Ear Infirmary","startDate":"2007-06","conditions":"Age Related Macular Degeneration","enrollment":20},{"nctId":"NCT00599222","phase":"PHASE3","title":"The Ranibizumab Plus Transpupillary Thermotherapy for Neovascular Age-Related Macular Degeneration (AMD) Study","status":"COMPLETED","sponsor":"Anders Kvanta","startDate":"2008-02","conditions":"Neovascular Age-related Macular Degeneration","enrollment":100},{"nctId":"NCT01102946","phase":"PHASE2","title":"Panretinal Photocoagulation (PRP) Plus Ranibizumab for Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2009-02","conditions":"Diabetic Retinopathy, Retinal Neovascularization","enrollment":40},{"nctId":"NCT00562406","phase":"NA","title":"Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES)","status":"COMPLETED","sponsor":"Klinikum Ludwigshafen","startDate":"2007-11","conditions":"Macular Edema","enrollment":30},{"nctId":"NCT00885794","phase":"PHASE2, PHASE3","title":"Microperimetry and Optical Coherence Tomography (OCT) With Lucentis for Diabetic Macular Edema (DME)","status":"UNKNOWN","sponsor":"The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery","startDate":"2008-05","conditions":"Diabetic Macular Edema","enrollment":40},{"nctId":"NCT00284050","phase":"PHASE2","title":"Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-10","conditions":"Diabetic Macular Edema","enrollment":151},{"nctId":"NCT01189526","phase":"PHASE3","title":"Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO)","status":"UNKNOWN","sponsor":"Seoul Retina Investigator Group","startDate":"2009-01","conditions":"Branch Retinal Vein Occlusion","enrollment":60},{"nctId":"NCT01123564","phase":"PHASE2","title":"Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion","status":"UNKNOWN","sponsor":"University of Pecs","startDate":"2009-08","conditions":"Retinal Vein Occlusion, Macular Edema","enrollment":40},{"nctId":"NCT00994799","phase":"","title":"Comparison of Intravitreal Ranibizumab and Macular Grid-pattern Laser for Treatment of Diabetic Macular Edema","status":"UNKNOWN","sponsor":"Szeged University","startDate":"2009-07","conditions":"Macular Edema","enrollment":50},{"nctId":"NCT00429962","phase":"PHASE3","title":"Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2006-07","conditions":"Choroidal Neovascularization, Age-Related Macular Degeneration","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":87,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ranibizumab and laser","genericName":"Ranibizumab and laser","companyName":"Fukushima Medical University","companyId":"fukushima-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ranibizumab blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth and leakage in the retina, while laser photocoagulation thermally destroys abnormal retinal tissue. Used for Proliferative diabetic retinopathy, Retinal vein occlusion with neovascularization.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}